Details

Autor(en) / Beteiligte

• Hoover, Ashley R
• Kaabinejadian, Saghar
• Krawic, Jason R
• Sun, Xiao-Hong
• Naqash, Abdul Rafeh
• Yin, Qian
• Yang, Xinbo
• Christopher Garcia, K
• Davis, Mark M
• Hildebrand, William H
• Chen, Wei R

Titel

Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors

Ist Teil von

• Journal for immunotherapy of cancer, 2022-10, Vol.10 (10), p.e004973

Ort / Verlag

England: BMJ Publishing Group Ltd

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Electronic Journals Library - Freely accessible e-journals

Beschreibungen/Notizen

• BackgroundLocalized ablative immunotherapies hold great promise in stimulating antitumor immunity to treat metastatic and poorly immunogenic tumors. Tumor ablation is well known to release tumor antigens and danger-associated molecular patterns to stimulate T-cell immunity, but its immune stimulating effect is limited, particularly against metastatic tumors.MethodsIn this study, we combined photothermal therapy with a potent immune stimulant, N-dihydrogalactochitosan, to create a local ablative immunotherapy which we refer to as laser immunotherapy (LIT). Mice bearing B16-F10 tumors were treated with LIT when the tumors reached 0.5 cm3 and were monitored for survival, T-cell activation, and the ability to resist tumor rechallenge.ResultsWe found that LIT stimulated a stronger and more consistent antitumor T-cell response to the immunologically ‘cold’ B16-F10 melanoma tumors and conferred a long-term antitumor memory on tumor rechallenge. Furthermore, we discovered that LIT generated de novo CD8+ T-cell responses that strongly correlated with animal survival and tumor rejection.ConclusionIn summary, our findings demonstrate that LIT enhances the activation of T cells and drives de novo antitumor T-cell responses. The data presented herein suggests that localized ablative immunotherapies have great potential to synergize with immune checkpoint therapies to enhance its efficacy, resulting in improved antitumor immunity.